Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.
The company is headquartered in Hampton, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 24, 25 | -0.71 Increased by +14.46% | -0.71 Increased by +0.64% |
| Oct 31, 24 | -0.64 Increased by +20.99% | -0.67 Increased by +4.48% |
| Aug 8, 24 | -0.54 Increased by +16.92% | -0.59 Increased by +8.47% |
| May 6, 24 | -0.56 Increased by +9.68% | -0.69 Increased by +18.84% |
| Feb 26, 24 | -0.83 Decreased by -48.21% | -0.74 Decreased by -12.16% |
| Nov 2, 23 | -0.81 Decreased by -42.11% | -0.68 Decreased by -19.12% |
| Aug 8, 23 | -0.65 Decreased by -10.17% | -0.67 Increased by +2.99% |
| May 4, 23 | -0.62 Decreased by -26.53% | -0.63 Increased by +1.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 1.18 M Decreased by -71.56% | -47.09 M Decreased by -8.74% | Decreased by -4.01 K% Decreased by -282.31% |
| Sep 30, 24 | 3.19 M Increased by +110.35% | -42.12 M Decreased by -10.09% | Decreased by -1.32 K% Increased by +47.66% |
| Jun 30, 24 | 2.50 M Increased by +832.09% | -35.84 M Decreased by -17.51% | Decreased by -1.43 K% Increased by +87.39% |
| Mar 31, 24 | 156.00 K Decreased by -83.87% | -32.81 M Decreased by -46.37% | Decreased by -21.03 K% Decreased by -807.28% |
| Dec 31, 23 | 4.13 M Increased by +156.11% | -43.31 M Decreased by -82.80% | Decreased by -1.05 K% Increased by +28.63% |
| Sep 30, 23 | 1.52 M Increased by +272.73% | -38.26 M Decreased by -53.29% | Decreased by -2.52 K% Increased by +58.87% |
| Jun 30, 23 | 268.00 K Increased by +64.42% | -30.50 M Increased by +41.98% | Decreased by -11.38 K% Increased by +64.71% |
| Mar 31, 23 | 967.00 K Increased by +455.75% | -22.41 M Decreased by -3.95% | Decreased by -2.32 K% Increased by +81.30% |